相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
Robert P. Perrillo et al.
GASTROENTEROLOGY (2015)
Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients With Resolved HBV Infection: A Prospective Study
Chiun Hsu et al.
HEPATOLOGY (2014)
Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy A Randomized Clinical Trial (vol 312, pg 2521, 2014)
He Huang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy A Randomized Clinical Trial
He Huang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours
W. H. Y. Ling et al.
BRITISH JOURNAL OF CANCER (2013)
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
Seok Jin Kim et al.
EUROPEAN JOURNAL OF CANCER (2013)
Off-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients
Wen-Juei Jeng et al.
HEPATOLOGY (2013)
Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B
Yi-Hsiang Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Hepatitis B virus reactivation associated with anti-neoplastic therapy
Winnie Yeo et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease
Fei W. Chen et al.
LIVER INTERNATIONAL (2013)
Clinical Prediction of Failure of Lamivudine Prophylaxis for Hepatitis B Virus-Infected Patients Undergoing Cytotoxic Chemotherapy for Malignancy
In Kyoung Kim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Yun-Fan Liaw et al.
HEPATOLOGY INTERNATIONAL (2012)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2012)
Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters
Tai-Chung Tseng et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy
H. -R. Li et al.
JOURNAL OF VIRAL HEPATITIS (2011)
Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide Analogues
Florian van Boemmel et al.
HEPATOLOGY (2010)
Rescue therapy for lamivudine-resistant chronic hepatitis B: Comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy
Hong Joo Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
Rohit Loomba et al.
ANNALS OF INTERNAL MEDICINE (2008)
Hepatitis B reactivation after chemotherapy: two decades of clinical research
George K. K. Lau
HEPATOLOGY INTERNATIONAL (2008)
Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy
Winnie Yeo et al.
HEPATOLOGY (2007)
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
TT Chang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
CL Lai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
W Yeo et al.
HEPATOLOGY (2006)
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy
CK Hui et al.
GUT (2005)
Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine
W Yeo et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2005)
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy
W Yeo et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy
W Yeo et al.
ANNALS OF ONCOLOGY (2004)
Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis
HLY Chan et al.
CLINICAL TRANSPLANTATION (2004)
Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study
W Yeo et al.
JOURNAL OF MEDICAL VIROLOGY (2003)
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
GKK Lau et al.
GASTROENTEROLOGY (2003)
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
ASF Lok et al.
GASTROENTEROLOGY (2003)
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
D Mutimer et al.
GUT (2000)
分享论文
